The Future of Antibody-Drug Conjugates and Oncogene-Directed Therapy in NSCLC

In the closing segment, faculty discuss the broader future of antibody-drug conjugate development beyond TROP2, reviewing agents directed at targets including MET and integrin beta-6, and the importance of payload selection and biomarker-guided patient selection. The panel explores how target biology, receptor internalization, and tumor microenvironment interactions influence efficacy, and why the most successful agents may be those directed at targets with functional relevance to the cancer. Faculty consider whether oncogene-directed therapy is moving toward integration across every line of treatment for driver-positive disease. The program concludes with closing reflections from each panelist, emphasizing comprehensive molecular testing, the expanding RAS therapeutic landscape, the potential convergence of targeted therapy and immunotherapy, and the promise of ctDNA and MRD-guided treatment decisions.